[ET Net News Agency, 5 August 2019] Ascletis Pharma Inc. (01672) said it has received
investigational new drug (IND) approval for ASC18, a one-pill once-a-day fixed dose
combination (FDC) as the complete treatment against hepatitis C, from China's National
Medical Products Administration.
The management team said it is confident in achieving the company's 2019 objectives of
reimbursement, research and development, and in-licensing clinical and commercial stage
assets while continuing to improve the company's financial performance. (RC)